Latest News and Press Releases

Paris, France – May 21, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, today announces the evolution of its Scientific Advisory Board (SAB). This renewed...

New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal...

Highly experienced in gene therapy dealmaking, Pettenaro will be driving Coave’s business development activities and establish its presence in the Boston biotech hub  Paris, France, and Cambridge,...

Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following...

Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...

Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...

PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US    Symptoms often start in childhood leading to blindness by midlife with no approved...

Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid,...

Paris, France, September 24, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company pioneering therapies for eye and neurodegenerative diseases, will present the first data on its...

          Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up           Phase I/II results will be discussed with US and...